Sequential single agents as first-line chemotherapy for ovarian cancer: a strategy derived from the results of GOG-132

This publication has 30 references indexed in Scilit:

• First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence
  British Journal of Cancer, 2002
• Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial
  The Lancet, 2002
• Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year Results
  JNCI Journal of the National Cancer Institute, 2000
• Phase III Randomized Study of Cisplatin Versus Paclitaxel Versus Cisplatin and Paclitaxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Oncology Group Study
  Journal of Clinical Oncology, 2000
• First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence
  British Journal of Cancer, 1998
• Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group.
  Journal of Clinical Oncology, 1998
• Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
  New England Journal of Medicine, 1996
• Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.
  Journal of Clinical Oncology, 1992
• Cis-platinum in the treatment of advanced or recurrent adenocarcinoma of the ovary
  American Journal of Clinical Oncology, 1983
• High-dose platinum for the treatment of refractory ovarian cancer
  Gynecologic Oncology, 1981